Overview

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

Status:
Withdrawn
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Collaborator:
Syndax Pharmaceuticals, Inc.
Treatments:
Entinostat